Indocyanine green (ICG) is one of the near-infrared fluorescent contrast agents approved for clinical use in fluorescence-guided surgery. Although widely applied, it still has some limitations. In recent years, various targeted fluorescent agents have been explored in pancreatic cancer patients; however, there is still no standardized consensus among surgeons regarding fluorescence-guided surgery for pancreatic cancer. In 2023, the first the international consensus report on fluorescent surgery navigation for pancreatic tumors was published, gathering perspectives from 38 pancreatic surgeons worldwide on current practices and future directions. A total of 76 statements were anonymously voted on using the Delphi method, resulting in 61 recommended statements. This consensus offers valuable guidance for the implementation of fluorescence-guided surgery in pancreatic tumor operations in China, yet its clinical application should be adapted in consideration of local expert opinions and patient-specific factors. This article interprets key aspects of the consensus, including the use of ICG, intraoperative fluorescence imaging techniques, and the fluorescence heterogeneity of pancreatic tumors, in combination with the authors' clinical experience, with the aim of providing reference and insight for the application of fluorescence-guided surgery in pancreatic tumors.